Latest news
Rami Manochakian: Lurbinectedin Faces FDA Withdrawal After Negative Phase 3 Trial in SCLC - OncodailyOncodaily · Sat, 08 Aug 2026 09:12:26 GMTJazz Seeks FDA Withdrawal of Second-Line Lurbinectedin SCLC Indication - MedscapeMedscape · Fri, 07 Aug 2026 08:24:31 GMTJazz to withdraw Zepzelca with FDA in second-line small cell lung cancer - Fierce PharmaFierce Pharma · Tue, 04 Aug 2026 13:18:16 GMTThis well-known medicine brand is being withdrawn from the market due to possible health risks - El CronistaEl Cronista · Sun, 02 Aug 2026 08:16:00 GMT